📊 IMDX Key Takeaways
Is IMDX a Good Investment? Thesis Analysis
Insight Molecular Diagnostics exhibits critical financial distress with negative stockholders equity of -$31.5M, indicating balance sheet insolvency. Operating losses of -$51.1M against $4.1M revenue and free cash flow burn of -$25.4M annually provide only ~5.5 months of cash runway at current burn rates, creating severe liquidity risk. While 56.7% gross margins and 3820% revenue growth suggest product viability, the company lacks a demonstrated path to profitability with operational expenses far exceeding revenues.
Why Buy IMDX? Key Strengths
- Strong gross margin of 56.7% indicates viable diagnostic product with pricing power
- Exceptional revenue growth of 3820% YoY demonstrates significant market traction and uptake
- Adequate short-term liquidity with current ratio of 1.27x and quick ratio of 1.23x
IMDX Investment Risks to Consider
- Negative stockholders equity of -$31.5M indicates technical balance sheet insolvency
- Free cash flow burn of -$25.4M annually against cash position of $11.6M provides only ~5.5 months operational runway
- Massive operating losses of -$51.1M with operating margin of -1260.8% show no path to profitability at current scale
Key Metrics to Watch
- Monthly cash burn rate and gross cash position runway
- Quarterly revenue growth sustainability and gross margin maintenance
- Operating expense trajectory and progress toward operating cash flow breakeven
IMDX Financial Metrics
💡 AI Analyst Insight
Insight Molecular Diagnostics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IMDX Profitability Ratios
IMDX vs Default Sector
How Insight Molecular Diagnostics Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IMDX Overvalued or Undervalued?
Based on fundamental analysis, Insight Molecular Diagnostics Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IMDX Balance Sheet & Liquidity
IMDX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Insight Molecular Diagnostics Inc.'s revenue has declined by 48% over the 5-year period, indicating business contraction. The most recent EPS of $-4.66 indicates the company is currently unprofitable.
IMDX Growth Metrics (YoY)
IMDX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $115.0K | -$10.9M | $-0.34 |
| Q2 2025 | $104.0K | -$4.5M | $-0.30 |
| Q1 2025 | $176.0K | -$6.7M | $-0.26 |
| Q3 2024 | $115.0K | -$6.5M | $-0.81 |
| Q2 2024 | $104.0K | -$4.5M | $-0.36 |
| Q1 2024 | $176.0K | $3.0M | $0.40 |
| Q3 2023 | $67.0K | -$6.5M | $-0.81 |
| Q2 2023 | $237.0K | -$5.3M | $-0.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IMDX Capital Allocation
IMDX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMDX
What is the AI rating for IMDX?
Insight Molecular Diagnostics Inc. (IMDX) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMDX's key strengths?
Claude: Strong gross margin of 56.7% indicates viable diagnostic product with pricing power. Exceptional revenue growth of 3820% YoY demonstrates significant market traction and uptake.
What are the risks of investing in IMDX?
Claude: Negative stockholders equity of -$31.5M indicates technical balance sheet insolvency. Free cash flow burn of -$25.4M annually against cash position of $11.6M provides only ~5.5 months operational runway.
What is IMDX's revenue and growth?
Insight Molecular Diagnostics Inc. reported revenue of $4.1M.
Does IMDX pay dividends?
Insight Molecular Diagnostics Inc. does not currently pay dividends.
Where can I find IMDX SEC filings?
Official SEC filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMDX's EPS?
Insight Molecular Diagnostics Inc. has a diluted EPS of $-1.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Insight Molecular Diagnostics Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMDX stock overvalued or undervalued?
Valuation metrics for IMDX: ROE of N/A (sector avg: 15%), net margin of -1,238.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMDX stock in 2026?
Our dual AI analysis gives Insight Molecular Diagnostics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMDX's free cash flow?
Insight Molecular Diagnostics Inc.'s operating cash flow is $-22.2M, with capital expenditures of $3.2M. FCF margin is -625.6%.
How does IMDX compare to other Default stocks?
Vs Default sector averages: Net margin -1,238.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.27 (avg: 1.8).